[
  {
    "measured_by": "≥2 antidepressant switches after adequate dose and duration",
    "justification": "“Treatment-resistant depression (TRD) is widely used as an outcome variable, broadly defined as ≥2 switches between antidepressant drugs prescribed for an adequate duration in individuals diagnosed with a depressive disorder.”",
    "construct": "Treatment-resistant depression"
  },
  {
    "measured_by": "electroconvulsive therapy (ECT) use",
    "justification": "“In other studies, TRD has been defined based on use of electroconvulsive therapy (ECT) derived from register data or medical records.”",
    "construct": "Treatment-resistant depression"
  },
  {
    "measured_by": "continued antidepressant prescription for ≥90 days",
    "justification": "“Using RWD, treatment stability has been defined as continued prescription of an antidepressant, for example for ≥90 days, as a proxy for treatment effectiveness.”",
    "construct": "Antidepressant treatment stability / effectiveness"
  },
  {
    "measured_by": "clozapine use",
    "justification": "“As it is primarily used for treatment-resistant SCZ, clozapine has been widely used in research as a proxy measure for non-response/treatment resistance both using clinical data and RWD.”",
    "construct": "Treatment-resistant schizophrenia"
  },
  {
    "measured_by": "antipsychotic polypharmacy (≥2 antipsychotics for ≥90 days)",
    "justification": "“Use of clozapine or antipsychotic polypharmacy defined as ≥2 antipsychotics for ≥90 days has been used as a proxy for treatment-resistant SCZ in a Swedish register study.”",
    "construct": "Treatment-resistant schizophrenia"
  },
  {
    "measured_by": "prescription of a third antipsychotic after two trials ≥6 weeks",
    "justification": "“In a study using eHRs, treatment-resistant SCZ was defined as either use of clozapine or prescription of a third new antipsychotic after two different antipsychotic prescriptions for ≥6 weeks.”",
    "construct": "Treatment-resistant schizophrenia"
  },
  {
    "measured_by": "readmission after discharge on clozapine",
    "justification": "“Using data from eHRs, ultra-treatment-resistant SCZ (i.e. non-response to clozapine) has been defined as readmission following an inpatient episode where the patient was discharged on clozapine.”",
    "construct": "Ultra-treatment-resistant schizophrenia"
  },
  {
    "measured_by": "Alda scale",
    "justification": "“Previous studies investigating treatment outcomes in BIP mainly include studies of lithium response assessed by the Alda scale (‘Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder’).”",
    "construct": "Lithium response"
  },
  {
    "measured_by": "hospitalization or second psychotropic drug within 6 months of lithium initiation",
    "justification": "“In a nationwide register-based study from Denmark, lithium nonresponse was defined as hospitalization at a psychiatric ward or prescription of a second psychotropic drug within six months after starting lithium treatment…”",
    "construct": "Lithium non-response"
  },
  {
    "measured_by": "time to discontinuation or add-on of another psychotropic medication",
    "justification": "“Using eHR data, treatment failure of mood stabilizers has been defined as time to discontinuation of the medication or add-on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine.”",
    "construct": "Mood stabilizer treatment failure"
  }
]